REG - Physiomics PLC - Notice of AGM

PhysiomicsAnnouncement

18/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231018:nRSR4234Qa&default-theme=true

RNS Number : 4234Q  Physiomics PLC  18 October 2023

18 October 2023

 

Physiomics plc

("Physiomics" or "the Company")

 

Notice of AGM

 

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions, is pleased to provide notice of the Company's Annual
General Meeting ("AGM").

 

The AGM will be held at 10.30 a.m. on 21 November 2023 at the Company's new
registered office, Bee House, 140 Eastern Avenue, Milton Park, Oxfordshire,
OX14 4SB.

 

Shareholders will shortly be sent either printed copies of the Notice of AGM
and accompanying materials or a letter notifying them that they are available
on the Company's website, depending on the preferences they have expressed to
the Company's registrar.

 

A copy of the Notice of AGM, containing further details of the resolutions, as
well as a copy of the Company's Annual Report and Accounts will be made
available today on the Company's website
at www.physiomics.co.uk/investors/reports-prospectus/
(https://www.physiomics.co.uk/investors/reports-prospectus/) .

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

 

About Physiomics

 

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with
cancer biology expertise, to help biotech and pharma companies streamline
their drug development journeys.

 

Our approach is to derive insight from all relevant data in order to de-risk
decision making and optimise design of pre-clinical and clinical studies.

 

Through use of bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 100 commercial
projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas,
Bicycle Therapeutics, Numab Therapeutics & CRUK.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAGZMMGDNLGFZM